1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
KOL Perspectives: Upadacitinib for Rheumatoid Arthritis
Summary
This KOL Insight briefing focuses on perceptions of novel upadacitinib data in RA.
The briefing includes analysis of KOL opinion on the following topic areas:
Key Highlights:
Scope
Reasons to buy
Summary
This KOL Insight briefing focuses on perceptions of novel upadacitinib data in RA.
The briefing includes analysis of KOL opinion on the following topic areas:
- Efficacy & safety of upadacitinib in the SELECT COMPARE trial (csDMARD-IR patients)
- Efficacy & safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial (MTX-IR patients)
- Views on dose response for upadacitinib
Key Highlights:
- Majority of KOLs had a positive opinion of upadacitinib’s efficacy, particularly vs. adalimumab, in the SELECT COMPARE trial
- Most KOLs had a favorable opinion of Week 12 upadacitinib data vs. adalimumab from the SELECT COMPARE trial
- KOLs appeared unsure of upadacitinib’s comparative efficacy vs. other JAK inhibitors, with many citing the need for head-to-head studies.
Scope
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based
- Interviews performed in Q2 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Upadacitinib for Rheumatoid Arthritis"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Background
Research Panel Composition
Results & Implications
Appendix
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- AbbVie
- Pfizer
- Lilly
- Gilead
- Galapagos
Note: Product cover images may vary from those shown
